Xiaoyi Yuan, Ph.D.
University of Texas Health Science Center at Houston
Evaluating Role of MicroRNA as Therapeutic Target for ARDS
Approximately 200,000 patients develop acute respiratory distress syndrome (ARDS) annually in the United States, leading to 75,000 deaths. In ARDS, fluid leaks into the lungs, making breathing difficult or impossible. There are no effective treatment or prevention strategies for this deadly disease. We have found that a group of small gene pieces called microRNAs are crucial molecules in changing the levels of inflammation in lung injury. We will study the role of a microRNA called miR-147 in lung inflammation in ARDS. We will evaluate whether these small genes can be targeted for ARDS treatment safely and efficiently in preclinical studies. Our study will lay the groundwork for novel therapeutic approaches for treating patients with ARDS.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.